Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check?

Archives of Internal Medicine

Volumn 170, Issue 1, 2010, Pages 27-40

  Ferket, Bart S ^a,b   Colkesen, Ersen B ^b,c   Visser, Jacob J ^a   Spronk, Sandra ^a   Kraaijenhagen, Roderik A ^b   Steyerberg, Ewout W ^a   Hunink, Myriam ^a,d,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NDDO Institute for Prevention and Early Diagnostics   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 75749102609     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.434     Document Type: Review

References (69)

1. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: World Health Organization; 2008.
2. Jackson R, Lynch J, Harper S. Preventing coronary heart disease. BMJ. 2006;332(7542):617-618.
3. van Wyk JT, van Wijk MA, Sturkenboom MC, Moorman PW, van der Lei J. Identification of the four conventional cardiovascular disease risk factors by Dutch general practitioners. Chest. 2005;128(4):2521-2527.
4. Mant D. Prevention. Lancet. 1994;344(8933):1343-1346.
5. Wonderling D, Langham S, Buxton M, Normand C, McDermott C. What can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses. BMJ. 1996;312(7041):1274-1278.
6. NHS Health Check: helping you prevent heart disease, stroke, diabetes and kidney disease. NHS Improvement Programme Web site. 2009. http://www. improvement.nhs.uk/vascularchecks/. Accessed May 4, 2009.
7. Prochazka AV, Lundahl K, Pearson W, Oboler SK, Anderson RJ. Support of evidence-based guidelines for the annual physical examination: a survey of primary care providers. Arch Intern Med. 2005;165(12):1347-1352.
8. Field M, Lohr K. Clinical Practice Guidelines: Directions for a New Program. Washington, DC: National Academy Press; 1990.
9. Grilli R, Magrini N, Penna A, Mura G, Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000;355(9198):103-106.
10. Graham ID, Harrison MB. Evaluation and adaptation of clinical practice guidelines. Evid Based Nurs. 2005;8(3):68-72.
11. Weingarten S. Using practice guideline compendiums to provide better preventive care. Ann Intern Med. 1999;130(5):454-458.
12. Shekelle PG, Ortiz E, Rhodes S, et al. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? JAMA. 2001;286(12):1461-1467.
13. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003;12(1):18-23.
14. AGREE Collaboration Web site. 2004. http://www.agreecollaboration.org/ instrument/. Accessed May 4, 2009.
15. National Institute for Health and Clinical Excellence. NICE clinical guideline 67 lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2008. http://www.nice.org.uk/nicemedia/pdf/ CG67NICEguideline.pdf. Accessed May 4, 2009.
16. Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease: a national clinical guideline. February 2007. http://www.sign.ac.uk/pdf/sign97.pdf. Accessed May 4, 2009.
17. Mosca L, Banka CL, Benjamin EJ, et al; Expert Panel/Writing Group; American Heart Association; American Academy of Family Physicians; American College of Obstetricians and Gynecologists; American College of Cardiology Foundation; Society of Thoracic Surgeons; American Medical Women's Association; Centers for Disease Control and Prevention; Office of Research on Women's Health; Association of Black Cardiologists; American College of Physicians; World Heart Federation; National Heart, Lung, and Blood Institute; American College of Nurse Practitioners. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115(11):1481-1501.
18. Goldstein LB, Adams R, Alberts MJ, et al; American Heart Association; American Stroke Association Stroke Council. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in Circulation. 2006;114(22):e617]. Circulation. 2006;113(24):e873- e923. doi:10.1161/01.STR.0000223048.70103.F1.
19. New Zealand Guidelines Group (NZGG). Assessment and management of cardiovascular risk. July 6, 2003. http://www.nzgg.org.nz/guidelines/dsp- guideline-popup.cfm?guidelineID=35&guideline-popup-mode=newsDisplay& NewsID=21. Accessed May 4, 2009.
20. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. 2007. http://www.who.int/cardiovascular-diseases/guidelines/PocketGL.ENGLISH.AFR-D-E. rev1.pdf. Accessed May 4, 2009.
21. Graham I, Atar D, Borch-Johnsen K, et al; European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; European Association for Study of Diabetes (EASD); International Diabetes Federation Europe (IDF-Europe); European Stroke Initiative (EUSI); Society of Behavioural Medicine (ISBM); European Society of Hypertension (ESH); WONCA Europe (European Society of General Practice/Family Medicine); European Heart Network (EHN); European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(suppl 2):S1-S113.
22. McPherson R, Frohlich J, Fodor G, Genest J; Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22(11):913-927.
23. Tonkin A, Barter P, Best J, et al; National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management-2005. Heart Lung Circ. 2005;14(4):275-291.
24. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(suppl 5):v1-v52.
25. Eyre H, Kahn R, Robertson RM, et al; American Cancer Society; American Diabetes Association; American Heart Association. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation. 2004;109(25):3244-3255.
26. Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J. 2007;28(16):2028-2040.
27. US Preventive Services Task Force. Screening for lipid disorders in adults: US Preventive Services Task Force recommendation statement. June 2008. http://www.ahrq.gov/CLINIC/uspstf/uspschol.htm. Accessed May 4, 2009.
28. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
29. National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. Lipid management guidelines - 2001: National Heart Foundation of Australia, the Cardiac Society of Australia and New Zealand. Med J Aust. 2001;175(suppl):S57-S85.
30. US Preventive Services Task Force. Screening for high blood pressure: US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2007;147(11):783-786.
31. Williams B, Poulter NR, Brown MJ, et al; British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens. 2004;18(3):139-185.
32. US Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;148(11):846-854.
33. National Health and Medical Research Council. National evidence based guidelines for the management of type 2 diabetes mellitus. 2005. http://www.nhmrc.gov.au/publications/synopses/di16to19syn.htm. Accessed May 4, 2009.
34. Rydén L, Standl E, Bartnik M, et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88-136.
35. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32(suppl 1):S1-S201.
36. Feig DS, Palda VA, Lipscombe L; Canadian Task Force on Preventive Health Care. Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. CMAJ. 2005;172(2):177-180.
37. Rodbard HW, Blonde L, Braithwaite SS, et al; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus [published correction appears in Endocr Pract. 2008;14(6):802-803]. Endocr Pract. 2007;13(suppl 1):1-68.
38. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels, Belgium: International Diabetes Federation; 2005.
39. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med. 2007;24(5):451-463.
40. American Diabetes Association. Standards of medical care in diabetes: 2009. Diabetes Care. 2009;32(suppl 1):S13-S61.
41. Diabetes UK. Position statement: early identification of people with type 2 diabetes. 2006. http://www.diabetes.org.uk. Accessed May 4, 2009.
42. Smith SC Jr, Jackson R, Pearson TA, et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation. 2004;109(25):3112- 3121.
43. Ballantyne C, Arroll B, Shepherd J. Lipids and CVD management: towards a global consensus. Eur Heart J. 2005;26(21):2224-2231.
44. McAlister FA, van Diepen S, Padwal RS, Johnson JA, Majumdar SR. How evidence-based are the recommendations in evidence-based guidelines? PLoS Med. 2007;4(8):e250.
45. National Guideline Clearinghouse Web site. 2009. http://www.guideline. gov/. Accessed May 4, 2009.
46. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365(9457):434-441.
47. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358(20):2107-2116.
48. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38(1):217-231.
49. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631-2639.
50. Beswick A, Brindle P. Risk scoring in the assessment of cardiovascular risk. Curr Opin Lipidol. 2006;17(4):375-386.
51. South-East London Screening Study Group. A controlled trial of multiphasic screening in middle-age: results of the South-East London Screening Study, 1977. Int J Epidemiol. 2001;30(5):935-940.
52. Han PK. Historical changes in the objectives of the periodic health examination. Ann Intern Med. 1997;127(10):910-917.
53. Wells S, Furness S, Rafter N, et al. Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice. Eur J Cardiovasc Prev Rehabil. 2008;15(2):173-178.
54. Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health. 2003;93(4):635-641.
55. Manuel DG, Kwong K, Tanuseputro P, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ. 2006;332(7555):1419.
56. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009; 373(9667):929-940.
57. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53(3):298-304.
58. Kahn SE. Glucose control in type 2 diabetes: still worthwhile and worth pursuing. JAMA. 2009;301(15):1590-1592.
59. Kearney PM, Blackwell L, Collins R, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-125.
60. Belch J, MacCuish A, Campbell I, et al; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) Trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. doi:10.1136/bmj.a1840.
61. Ogawa H, Nakayama M, Morimoto T, et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134-2141.
62. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med. 2005;22(5):554-562.
63. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care. 2007;30(5):1292-1293.
64. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S; Swedish National Diabetes Register. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care. 2008;31(10):2038-2043.
65. Simmons RK, Sharp S, Boekholdt SM, et al. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med. 2008;168(11):1209-1216.
66. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396-404.
67. Unwin N, Thomson R, O'Byrne AM, Laker M, Armstrong H. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. BMJ. 1998;317(7166):1125-1130.
68. Oxman AD, Glasziou P, Williams JW Jr. What should clinicians do when faced with conflicting recommendations? BMJ. 2008;337:a2530.
69. IOM (Institute of Medicine). Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academies Press; 2009.